Screen-detected multiple primary lung cancers in the ITALUNG trial by Mascalchi, M. et al.
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018;10(2):1058-1066jtd.amegroups.com
Short Communication
Screen-detected multiple primary lung cancers in the ITALUNG trial
Mario Mascalchi1, Camilla E. Comin2, Elena Bertelli1, Lapo Sali1, Cristina Maddau3, Stefania Zuccherelli1, 
Giulia Picozzi3, Laura Carrozzi4, Michela Grazzini5, Gabriella Fontanini6, Luca Voltolini7, Alessandra 
Vella8, Francesca Castiglione2, Francesca Carozzi3, Eugenio Paci3, Maurizio Zompatori9, Andrea Lopes 
Pegna10, Fabio Falaschi11; for the ITALUNG Study Research Group*
1“Mario Serio” Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy; 2Division of Pathological 
Anatomy, Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy; 3Institute for Cancer Research and Prevention 
(ISPO), Florence, Italy; 4Cardiopulmonary Department, Pisa University Hospital, Pisa, Italy; 5Pulmonology Department, Hospital of Pistoia, 
Pistoia, Italy; 6Pathology Department, University Hospital of Pisa, Pisa, Italy; 7Division of Thoracic Surgery, Careggi University Hospital, Florence, 
Italy; 8Service of Nuclear Medicine, Le Scotte Hospital, Siena, Italy; 9Radiology Department, Multimedica Group, IRCCS, Sesto San Giovanni, 
Italy; 10Pulmonology, Cardio-Thoracic-Vascular Department, Careggi Hospital, Florence, Italy; 112nd Radiology Unit, University Hospital of Pisa, 
Pisa, Italy
Correspondence to: Lapo Sali, MD, PhD. “Mario Serio” Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale 
Morgnagni 50, 50134 Florence, Italy. Email: lapo.sali@unifi.it.
Abstract: Occurrence of multiple primary lung cancers (MPLC) in individuals undergoing low-dose 
computed tomography (LDCT) screening has not been thoroughly addressed. We investigated MPLC in 
subjects recruited in the ITALUNG randomized clinical trial. Cases of cytologically/histologically proven 
MPLC detected at screening LDCT or follow-up CT were selected and pathologically re-evaluated 
according to the WHO 2015 classification. Overall 16 MPLC were diagnosed at screening LDCT (n=14, all 
present at baseline) or follow-up CT (n=2) in six subjects (4 in one subject, 3 in two and 2 in three subjects), 
representing 0.43% of the 1,406 screenees and 15.8% of the 38 subjects with at least one screen-detected 
primary lung cancer. MPLC included 9 adenocarcinomas in three subjects and a combination of 7 different 
tumour histotypes in three subjects. MPLC, mostly adenocarcinomas, are not uncommon in smokers and  
ex-smokers with at least one LDCT screen detected primary lung cancer.
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Introduction
Smoking makes pulmonary tissue diffusely prone to 
cancer development (“field cancerization” theory) (1,2). 
Accordingly, smokers and former smokers can develop 
multiple lung cancers in their lives. Available data on 
multiple primary lung cancers (MPLC) derive mainly 
from surgical series (3). However, low-dose computed 
tomography (LDCT) screening can provide an alternative 
source of information about MPLC. To the best of our 
knowledge, so far this has not been thoroughly addressed. 
We reviewed the occurrence and type of MPLC in 
subjects undergoing LDCT screening in the ITALUNG 
randomized clinical trial (4).  
Methods
ITALUNG is a randomized clinical trial carried out in Italy 
evaluating efficacy of LDCT screening in reducing lung 
cancer mortality as compared to “usual care” (5). The study 
was conducted in compliance with the Helsinki Declaration 
(http://www.wma.net/en/30publications/10policies/b3/
index.html) and the study protocol was approved by the 
Local Ethic Committees of the participating centers 
(Firenze, approval number 29–30, 30 September 2003; Pisa, 
number 23, 27 October 2003; Pistoia, number 00028543, 
13 May 2004). Each subject provided an informed written 
consent to participate to the study. 
The ITALUNG study design and protocol were 
previously reported (6,7). Briefly, 3,206 smokers or former 
smokers identified by general practitioners and invited 
by mail were randomized to receive four annual LDCT 
(n=1,613) or usual care (n=1,593). Management protocol 
for positive LDCT examinations included follow-up 
LDCT, 2-[18F]fluoro-2-deoxy-D glucose positron emission 
tomography, and CT-guided fine-needle aspiration 
biopsy (FNAB).
Follow-up data at 8.5 years in ITALUNG indicated that 
LDCT screening could reduce lung cancer and overall 
mortality (4). In the actively screened arm, 1,406 smokers or 
former smokers (910 men with mean age of 61.1 years and 
496 women with mean age of 60.6 years) underwent annual 
screening LDCT at baseline and in the next 3 years. 
In ITALUNG the subjects with screen-detected primary 
lung cancer entered follow-up with contrast-enhanced full-
dose head, chest and abdomen CT that was performed 
every 6 months for the first 2 years and annually for 3 years 
thereafter. All subjects with screen-detected primary lung 
cancer had completed the 5 years of follow-up CT at the 
time of writing.
For identification of MPLC in ITALUNG we applied a 
three step procedure (see below) and the criteria proposed 
by Shen et al. (8) that define 3 types of lesions: (I) those that 
share the same histology but are distributed in different 
pulmonary lobes, in absence of N2, N3 or systemic 
metastases; (II) those that show different histological or 
molecular-genetic characteristics and arise separately from 
foci of carcinoma in situ; (III) those that share the same 
histology but are separated by at least 4 years interval and 
without systemic metastases between the detection of 
multiple tumors. 
The three step procedure included the following:
(I) Step 1: records of all screened subjects with 
diagnosis of lung cancer based on the results 
of FNAB or surgical pathology during LDCT 
screening or ful l-dose CT follow-up were 
reviewed searching for cases of multiple primary or 
secondary lung cancer.
(II) Step 2: one experienced lung pathologist (C.E.C) 
reviewed and classified all the surgical or fine needle 
aspiration specimens of the selected cases according 
to the 2015 WHO criteria taking into account 
morphology and molecular/genetic features (9,10). 
The ITALUNG pathology protocol referred to the 
EU-US shared pathology protocol for CT-screening 
trials (EU-US Spiral CT Collaborative Group) and 
is detailed in supplementary material. Pathologic or 
clinical staging of MPLC was performed according 
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to the 7th Edition of the American Joint Committee 
on Cancer Staging Manual (11).
(III) Step 3: two senior chest radiologists (M.M. 
and F.F.) reviewed all the LDCT and follow-up 
full-dose CT examinations of the subjects with 
pathologically confirmed MPLC. They established 
the first LDCT or follow-up CT showing focal 
abnormalities that were ultimately diagnosed as 
lung cancer and described them (12).
Results
Eight subjects were diagnosed with multiple lung cancers 
during LDCT screening or full-dose CT follow-up. Two 
had multiple secondary lesions (from renal cancer and 
colorectal cancer) detected at LDCT and diagnosed at 
FNAB. Six subjects were ultimately diagnosed with MPLC 
(overall =16:2 in three subjects, 3 in two subjects and 4 in 
one subject) (Table 1 and Figures 1,2). They represented 
15.8% (6/38) of all subjects with at least one screen-
detected primary lung cancer.
The 16 MPLC included 9 morphologically and 
molecularly heterogeneous adenocarcinomas in three 
subjects (Figure 1) and combination of different tumor 
histotypes (2 adenocarcinomas plus 1 carcinoid, 1 
adenocarcinoma plus 1 small cell carcinoma, 1 pleomorphic 
carcinoma plus 1 squamous cell carcinoma) in three subjects 
(Figure 2). Adenocarcinomas accounted for 75% (12/16) 
of MPLC.
Fourteen of 16 MPLC were observed during LDCT 
screening in four subjects and 2 during full-dose CT follow-
up in two subjects. All the former were already present 
at baseline LDCT examination (Figures 1,2) and may be 
considered as synchronous lesions. The latter appeared 
during follow-up CT 5 and 6 years after surgical removal 
of the first lesions and may be considered metachronous 
lesions. Overall, MPLC appeared in the LDCT or follow-
up CT in which they were retrospectively identified for the 
first time as solid (n=9), partially solid (n=3), non-solid (n=3) 
or excavated (n=1) lesions with regular (n=7), ill-defined 
(n=5), spiculated (n=2), irregular or lobulated (n=2) margins. 
Their initial size ranged between 4 and 32 mm (mean 
diameter 14.4±8.1 mm).
Of the three subjects with 2 lesions, one died of surgical 
complication and two of advanced disease. Of the three 
subjects with more than 2 lesions, two are alive (10 and 
11 years after treatment of multifocal adenocarcinomas) and 
one died of advanced disease.
Discussion
Data about occurrence of MPLC in observational or 
randomized LDCT screening studies are fragmentary and 
summarized in Table 2. At least one subject with MPLC 
was reported in 11/33 studies (5,13-18,24-35), with a mean 
cumulative frequency of 0.18% (136 subjects) in 71,901 
screenees and of 11.6% in 1,170 subjects with at least one 
screen-detected lung cancer (19-23,36-44). The MPLC 
were considered synchronous in 123/136 (90%) subjects and 
metachronous in 13 (10%). Unfortunately, in many cases 
the time of lesions appearance and histological diagnoses 
were not available. Moreover uncertainties and intervening 
modifications of the staging system of lung cancer and 
unavailability of morphologic and genetic/molecular 
features hinder recollection of information about MPLC in 
previous reports of LDCT screening (and surgical series). 
In particular, multiple pulmonary nodules may have been 
considered stage III or IV tumors (18), and this may have 
led to under-reporting of cases of MPLC, especially in case 
of multifocal adenocarcinoma. 
In the active arm of ITALUNG, after the 4 years of 
active screening and 5 years of follow-up we observed 
few subjects (n=6; 0.43% of the screenees) harboring or 
developing MPLC. However they represented 15.8% of 
all those subjects with at least one screen-detected primary 
lung cancer. These percentages are in line with those 
reported in LDCT screening studies (Table 2).
In our series, adenocarcinoma was the most frequent 
histotype. This is in line with the type of primary lung 
cancers that are discovered by LDCT (Table 1) and in a 
previous study (18). Despite the small numbers of MPLC 
cases in our study that indicates need of further studies, two 
scenarios may be drawn. The first deals with morphological 
and molecular/genetically heterogeneous multifocal 
adenocarcinomas. The second deals with combination of 
adenocarcinoma with others histological types including 
small cell lung cancer, carcinoid and squamous cell cancer. 
Only one case of double squamous lung cancer was 
reported (23). As in previous reports (19,22), most (14/16 
lesions in five subjects) of the screen-detected MPLC in 
ITALUNG were present at baseline and were diagnosed 
after further LDCT screening rounds, because of increased 
size or density (12,17,27).
Remarkably, our two patients with synchronous 
mult i focal  adenocarcinoma with 4 and 3 les ions, 
respectively, were alive many years after lesion treatment. 
This  i s  consis tent  with the v iew that  mult i focal 
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Figure 1 Case I (Table 1). Four primary adenocarcinomas in a 70-year-old smoker, which were all detected at baseline LDCT screening 
round. They appeared as a spiculated lung nodule in the right upper lobe (RUL) (A), a ground glass opacity in the same lobe (B), a small 
solid nodule in the right lower lobe (RLL) (arrow in C) and a ground glass opacity with a small solid component in the left upper lobe (LUL) 
(D). Haematoxylin and eosin histologic staining (original magnification ×200) demonstrate an invasive adenocarcinoma, acinar predominant 
(E) in the RUL lesion corresponding to (A), an invasive adenocarcinoma, lepidic predominant (F) in the RUL lesion corresponding to (B) 
and an invasive adenocarcinoma, acinar predominant (G) in the RLL lesion corresponding to (C). Papanicolaou stain (original magnification 
×40) of fine needle aspiration biopsy shows papillary pattern of uniform malignant cells with irregular nuclei consistent with adenocarcinoma 
(H) in the LUL lesion corresponding to (D).
adenocarcinoma can behave as indolent lesion that should 
not be confused with aggressive primary lung cancers with 
intrapulmonary metastases (18). Awareness of this possibility 
may have significant impact on management of multiple 
lesions detected at LDCT screening that is currently 
recommended in the US (39) and is under evaluation in 
Europe (4).
In ITALUNG after a median follow-up time of 
8.5 years, we observed 2 metachronous cancers during 
full-dose CT follow-up, which were both fatal. Obviously, 
longer surveillance is expected to increase the yield of 
metachronous MPLC. In fact one LDCT study reported 
6 cases of metachronous MPLC in 2,989 screenees followed 
for 14 years (23).
Prevalence of MPLC in 18 surgical series outside 
screening (mean range, 1.1–8.6%) (3) was lower than the 
frequency in LDCT screening studies reporting at least one 
such a case. This is not surprising since subjects undergoing 
LDCT are asymptomatic and prone to show developing 
cancers in their earlier stages.
Occurrence of MPLC in a single subject per se suggests 
the possibility of genetic predisposition. However search of 
genetic features associated with lung cancer (45) was beyond 
the scope of the present report.
Admittedly, since our study is based on cytopathologically 
or histopathologically proven primary lung cancer, it is 
possible that we underestimated MPLC in the cohort 
of subjects undergoing LDCT screening. In particular, 
lesions presenting as pure ground glass opacity that can be 
associated with minimally invasive adenocarcinoma (9) may 
be missed.
In conclusion, MPLC, mostly adenocarcinomas, are 
not uncommon in smokers and former smokers with at 
least one LDCT screen detected primary lung cancer. The 
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Nawa et al. 2002 (13) 7,956 1 40 (0.5) 39 1 (synchronous) 2.5
Diederich et al. 2002 (14) 817 4 11 (1.3) 5 1 (synchronous) 9.0
Flieder et al. 2006 (15) 2,968 11 77 (2.6) 81 16 (synchronous) 20.8
Carter et al. 2007 (16) 10,056 11 250 (2.5) 177 31 (synchronous),  
5 (metachronous)
14.4
Lindell et al. 2007 (17) 1,520 5 59 (3.9) 34 1 (synchronous),  
1 (metachronous)
3.4
Pelosi et al. 2008 (18) 5,202 3 89 (1.7) 72 10 (synchronous) 11.2
Vazquez et al. 2009 (19) 27,456 12 338 (1.2) 279 49 (synchronous) 14.5
van Klaveren et al. 2009 (20) 7,557 3 124 (1.6) NA 5 (synchronous) 4.0
Infante et al. 2009 (21) 1,276 4 60 (4.7) 27 2 (synchronous),  
1 (metachronous)
5.0
Saghir et al. 2012 (22) 4,104 5 69 (1.7) 48 6 (synchronous) 8.7





Figure 2 Case II (Table 1). Adenocarcinoma and small cell lung cancer in a 61-year-old smoker both detected at baseline LDCT screening 
round. They appeared as a rounded lung nodule in the RUL and a subpleural small solid nodule (arrow) in the LUL (A). Haematoxylin and 
eosin histologic staining demonstrate invasive adenocarcinoma, acinar predominant (original magnification ×200) (B) in the RUL lesion and 
small cell lung carcinoma (original magnification ×100) (C) in the LUL lesion.
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potential distinction of two subtypes of MPLC, represented 
by multifocal adenocarcinomas and by combination of 
adenocarcinoma with others histological types, having 
different prognoses and treatment implications warrants 
further study.
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Tumors were sampled as fresh tissue immediately 
after surgery. The entire tumors, fragments of distant 
non-neoplastic parenchyma, all detectable lymph nodes, 
and mediastinal lymph nodes were sampled. Specimens 
were fixed in buffered formalin for 16–24 hours and 
processed for standard histological examination. Multiple 
adenocarcinoma cases underwent molecular analysis for the 
identification of ALK gene translocation and of the known 
driver mutations in the following genes: EGFR, KRAS, 
NRAS, BRAF, PIKCA, ERBB2, DDR2, MAP2K1 and 
RET. A representative paraffin-embedded block containing 
about 80% viable tumor was selected for each case. 
Immunohistochemical staining procedures were conducted 
on 4 µm-thick sections of paraffin-embedded tissue using 
a Ventana Benchmark Ultra automated immunostainer 
(Ventana Medical System, Tucson, AZ, USA) with the 
anti-ALK monoclonal antibody (clone D5F3, ready to use, 
Ventana Medical System). The OptiView DAB Detection 
kit was used as revelation system, adding the OptiView 
Amplification kit (Ventana Medical System) for ALK 
detection. Three consecutive 10 µm-thick sections were 
performed from the same blocks for molecular analysis. 
These were conducted by a mass spectrometry-based 
multiplex assay (MassArray technology, Sequenom, 
San Diego, CA) using the “Myriapod Lung Status” kit 
(Diatech Pharmacogenetics, AN, IT) capable of identifying 
the major mutations of the following genes: EGFR 
(exons 18, 19, 20, 21), KRAS (codons 12, 13, 61), NRAS 
(codons 12, 61), BRAF (codons 466, 469, 594, 597, 
600), PIKCA (codons 542, 545, 1043, 1047), ERBB2 
(exon 20), DDR2 (codons 239, 638, 768), MAP2K1 
(codons 56, 57, 67), RET (codon 918). 
